Literature DB >> 3951331

Effect of ipriflavone on the response of uterus and thyroid to estrogen.

I Yamazaki.   

Abstract

Ipriflavone, 7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one, was uterotropic in intact but not in ovariectomized rats. When it was administered simultaneously with estrone and estradiol-17 beta to ovariectomized rats, ipriflavone increased the uterotropic activities of both estrogens. The uterotropic activity of this compound in intact rats might be attributable to its action on the target organ of estrogen by augmenting the response to the hormone because none of the other possibilities for accelerating uterine growth such as gonadotropin-releasing, gonadotropic, and estrogen metabolism-retarding activities were demonstrated experimentally. In addition, ipriflavone increased the calcitonin releasing activity of estrone when these compounds were administered simultaneously to ovariectomized rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951331     DOI: 10.1016/0024-3205(86)90591-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.

Authors:  D Agnusdei; C Gennari; L Bufalino
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

Review 2.  Ipriflavone influences the osteoblastic phenotype in vitro.

Authors:  M L Brandi
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

3.  Lack of effect of ipriflavone on osteoclast motility and bone resorption in in vitro and ex vivo studies.

Authors:  M Azria; C Behhar; S Cooper
Journal:  Calcif Tissue Int       Date:  1993-01       Impact factor: 4.333

4.  Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

Authors:  S Adami; L Bufalino; R Cervetti; C Di Marco; O Di Munno; L Fantasia; G C Isaia; U Serni; L Vecchiet; M Passeri
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females.

Authors:  S Nakamura; S Morimoto; S Takamoto; T Onishi; K Fukuo; E Koh; S Kitano; Y Miyashita; O Yasuda; M Tamatani
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

6.  Histochemical and fine structural study of bone of ipriflavone-treated rats.

Authors:  H Ozawa; H Nakamura; K Irie; M Irie
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

7.  Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells.

Authors:  Y Kakai; T Kawase; T Nakano; Y Mikuni-Takagaki; S Saito
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

8.  Effects of ipriflavone on calcitonin synthesis in C cells of the rat thyroid.

Authors:  K Watanabe; S Takekoshi; K Kakudo
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

9.  Ipriflavone inhibits murine osteoclast formation in vitro.

Authors:  I Morita; K Sakaguchi; T Kurachi; S Murota
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

10.  Lack of any estrogenic effect of ipriflavone in postmenopausal women.

Authors:  G B Melis; A M Paoletti; A Cagnacci; L Bufalino; A Spinetti; M Gambacciani; P Fioretti
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.